Abstract
Purpose. To examine the structure–activity relationships for the inhibition of the activity of recombinant human CYP3A4 and to establish a generalized, quantitative physicochemical model for use in early drug discovery.
Methods. Inhibition of the activity of recombinant human CYP3A4 (erythromycin N–demethylase) by 30 diverse chemicals was studied using enhanced throughput methodology.
Results. There was a general, strong correlation between the IC50 value determined against erythromycin N–demethylase activity and lipophilicity (LogD7.4) (r 2 = 0.68, p <0.0001). This relationship was strengthened further by subdividing the structures studied into two distinct subpopulations of chemistry within the dataset. These could be identified by the absence (r 2 = 0.80, p <0.0001) or presence (r 2 = 0.69, p <0.0001) of a sterically uninhindered N–containing heterocycle, more specifically a pyridine, imidazole, or triazole function. The presence of these structural motifs increased the potency of CYP3A4 inhibition by approximately 10–fold for a given lipophilicity (LogD7.4.value). More detailed analyses of AstraZeneca compounds demonstrated that the inhibitory potency of the pyridine structure can be attenuated through direct steric effects or electronic substitution resulting in a modulation of the pKa of the pyridine nitrogen, thereby influencing its ability to interact with the CYP heme.
Conclusions. A generalized, quantitative model is proposed for the inhibition of the major drug metabolizing enzyme, CYP3A4. This model indicates the importance of lipophilicity and rationalizes increased potency arising through additional interactions with the heme iron. These general relationships were shown to be applicable to a selection of compounds of interest to several early research projects.
Similar content being viewed by others
REFERENCES
T. Shimada, H. Yamazaki, M. Mimura, I. Yukiharu, and F. P. Guengerich. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414–423 (1994).
R. J. Bertz and G. R. Granneman. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:210–258 (1997).
J. H. Lin and A. Y. H. Lu. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35:361–390 (1998).
P. K. Honig, D. C. Wortham, K. Zamani, D. P. Conner, J. C. Mullin, and L. R. Cantilena. Terfenadine–ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513–1518 (1993).
S. R. Ahmad and S. M. Wolfe. Cisapride and torsades de pointes. Lancet 345:508 (1995).
J.C. Krayenbuhl S. Vozeh. M. Kondo–Oestreicher, and P. Dayer P. Drug–drug interactions of new active substances: Mibefradil example. Eur. J. Clin. Pharmacol. 55:559–565 (1999).
C. C. Peck, R. Temple, and J. M. Collins. Understanding consequences of concurrent therapies. JAMA 269: 1550–1552 (1993).
J. Halpert, T. L. Domanski, O. Adali, C. P. Biagini, P. Cosme, E. A. Dierks, E. F. Johnson, J. P. Jones, P. Ortiz de Montellano, R. M. Philpot, O. Sibbesen, K. W. Wyatt, and Z. Zheng, Z. Structure–function of cytochromes P450 and flavin–containing monooxygenases: implications for drug metabolism. Drug Metab. Dispos. 26:1223–1231 (1998).
L. Pichard, J. Domergue, G. Fourtanier, P. Koch, H. F. Schran, and P. Maurel. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. Biochem. Pharmacol. 51:591–598 (1996).
S. Ekins, G. Bravi, S. Binkley, J. S. Gillespie, B. J. Ring, J. H. Wikel, and S. A. Wrighton. Three–and four–dimensional quantitative structure activity relationship analyses of cytochrome P450–3A4 inhibitors. J. Pharmacol. Exp. Ther. 290:429–438 (1999).
G. C. Moody, S. J. Griffin, A. N. Mather, D. F. McGinnity, and R. J. Riley. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential. Xenobiotica 29:53–75 (1999).
D. F. McGinnity, S. J. Griffin, G. C. Moody, M. Voice, S. Hanlon, T. Friedberg, and R. J. Riley. Rapid characterization of the major drug–metabolizing human hepatic cytochrome P–450 enzymes expressed in Escherichia coli. Drug Metab. Dispos. 27:1017–1023 (1999).
R. J. Riley and D. Howbrook. In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N–methyl 14 C]erythromycin. J. Pharmacol. Toxicol. Meth. 38:189–193 (1998).
Y. Cheng and W. H. Prusoff, WH. Relationship between the inhibition constant (Ki) and the concnetration of an inhibitor that causes a 50% inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099–3108 (1973).
L. Pichard, I. Fabre, G. Fabre, J. Domergue, B. S. Aubert, G. Mouard, and P. Maurel. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18:595–606 (1990).
K.E. Kenworthy, J. C. Bloomer, S. E. Clarke, and J. B. Houston. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 48:716–727 (1999).
R. W. Wang, D. J. Newton, N. Liu, W. M. Atkins, and A. Y. Lu. Human cytochrome P–450 3A4: in vitro drug–drug interaction patterns are substrate–dependent. Drug Metab. Dispos. 28:360–366 (2000).
D. A. Smith, S. M. Abel, R. Hyland, and B. Jones. Human cytochrome P450s: Selectivity and measurement in vivo. Xenobiotica 28:10957–1128 (1998).
C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:3–27 (1997).
D. A. Smith. Drug metabolism: Towards the next millenium. Biomed. Health Res. 25:137–43 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Riley, R.J., Parker, A.J., Trigg, S. et al. Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery. Pharm Res 18, 652–655 (2001). https://doi.org/10.1023/A:1011085411050
Issue Date:
DOI: https://doi.org/10.1023/A:1011085411050